BRPI0508633A - identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes - Google Patents

identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes

Info

Publication number
BRPI0508633A
BRPI0508633A BRPI0508633-7A BRPI0508633A BRPI0508633A BR PI0508633 A BRPI0508633 A BR PI0508633A BR PI0508633 A BRPI0508633 A BR PI0508633A BR PI0508633 A BRPI0508633 A BR PI0508633A
Authority
BR
Brazil
Prior art keywords
self
identification
involved
autoimmune diseases
methods
Prior art date
Application number
BRPI0508633-7A
Other languages
English (en)
Inventor
James Rasmussen
Bei Yu
Original Assignee
Peptimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptimmune Inc filed Critical Peptimmune Inc
Publication of BRPI0508633A publication Critical patent/BRPI0508633A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

IDENTIFICAçãO DE ANTìGENOS PRóPRIOS E NãO PRóPRIOS ENVOLVIDOS EM DOENçAS AUTO-IMUNES A presente invenção proporciona peptídeos isolados relacionados à doença auto-imune pênfigo vulgar. Os peptídeos relacionados ao pênfigo vulgar são epítopos próprios derivados de patógenos humanos que estão envolvidos na etiologia e remissão da doença. Preparações farmacêuticas para tolerização e/ou imunização dos indivíduos são proporcionadas, bem como métodos relacionados aos mesmos. Métodos são proporcionados para identificação de outros epítopos próprios e não próprios envolvidos na doença auto-imune humana e preparações farmacêuticas similares e métodos de uso para estes epítopos são também fornecidos.
BRPI0508633-7A 2004-03-11 2005-03-10 identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes BRPI0508633A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/799,005 US7084247B2 (en) 2004-03-11 2004-03-11 Identification of self and non-self antigens implicated in autoimmune diseases
PCT/US2005/008326 WO2005087261A2 (en) 2004-03-11 2005-03-10 Identification of self and non-self antigens implicated in autoimmune diseases

Publications (1)

Publication Number Publication Date
BRPI0508633A true BRPI0508633A (pt) 2007-08-07

Family

ID=34920407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508633-7A BRPI0508633A (pt) 2004-03-11 2005-03-10 identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes

Country Status (17)

Country Link
US (2) US7084247B2 (pt)
EP (1) EP1732595A2 (pt)
JP (1) JP2007528422A (pt)
KR (1) KR20070026450A (pt)
CN (1) CN1942202A (pt)
AP (1) AP2006003735A0 (pt)
AU (1) AU2005221712A1 (pt)
BR (1) BRPI0508633A (pt)
CA (1) CA2559065A1 (pt)
EA (1) EA200601671A1 (pt)
IL (1) IL177961A0 (pt)
MA (1) MA28525B1 (pt)
MX (1) MXPA06010364A (pt)
NO (1) NO20064610L (pt)
TN (1) TNSN06273A1 (pt)
WO (1) WO2005087261A2 (pt)
ZA (1) ZA200607552B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084247B2 (en) * 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
JP5225092B2 (ja) * 2005-10-14 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チピファルニブの新規ｉｖ調合物
BRPI0706400A2 (pt) * 2006-01-17 2011-03-29 Organon Nv processos para a hidrólise enzimática seletiva de terc-butil ésteres c-terminais de substratos de peptìdeo, para a sìntese convergente de um peptìdeo de dois ou mais fragmentos de peptìdeo, para a sìntese enzimática por etapas de um peptìdeo na direção do terminal c, e para a sìntese de peptìdeo
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
JP2009069050A (ja) * 2007-09-14 2009-04-02 Nec Corp 化合物のカラム担体への固定化方法
KR101751406B1 (ko) * 2007-10-16 2017-06-27 펩팀문, 인코포레이티드 에피토프의 지정 확장에 의해 지정 서열 중합체 조성물을 포함하는 백신을 설계하고 제조하는 방법
US8546532B2 (en) * 2008-04-17 2013-10-01 Declion Pharmaceuticals, Inc. Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
ATE551369T1 (de) 2008-11-17 2012-04-15 Borealis Ag Mehrstufiger prozess zur herstellung von polyethylen mit reduzierter gelbildung
EP2430442B1 (en) * 2009-05-14 2015-04-01 Oatmeal Biotechnologies Group, L.L.C. Platform technologies for spontaneously occurring diseases
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
EP2570455A1 (en) 2011-09-16 2013-03-20 Borealis AG Polyethylene composition with broad molecular weight distribution and improved homogeneity
EP2599828A1 (en) 2011-12-01 2013-06-05 Borealis AG Multimodal polyethylene composition for the production of pipes with improved slow crack growth resistance
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
ES2604934T3 (es) 2012-11-09 2017-03-10 Abu Dhabi Polymers Company Limited (Borouge) Composición polimérica que comprende una mezcla de un polietileno multimodal y un polímero de etileno adicional adecuado para la fabricación de un tubo de riego por goteo
ES2613070T3 (es) 2012-11-09 2017-05-22 Abu Dhabi Polymers Company Limited (Borouge) Tubería de riego por goteo que comprende una composición polimérica que comprende una resina base de polietileno multimodal
EP2740761B1 (en) 2012-12-05 2016-10-19 Borealis AG Polyethylene composition with improved balance of slow crack growth resistance, impact performance and pipe pressure resistance for pipe applications
EP2860202B1 (en) 2013-10-10 2018-05-30 Borealis AG High temperature resistant polyethylene and process for the production thereof
EP2860200B1 (en) 2013-10-10 2017-08-02 Borealis AG Polyethylene composition for pipe and pipe coating applications
EP2860204B1 (en) 2013-10-10 2018-08-01 Borealis AG Polyethylene composition for pipe applications
EP2860201A1 (en) 2013-10-10 2015-04-15 Borealis AG High temperature resistant polyethylene and process for the production thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932798C (en) * 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3166968B1 (en) * 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3647645A1 (en) 2018-10-31 2020-05-06 Borealis AG Polyethylene composition for high pressure resistant pipes
WO2020088987A1 (en) 2018-10-31 2020-05-07 Borealis Ag Polyethylene composition for high pressure resistant pipes with improved homogeneity
EP3887410A1 (en) 2018-11-28 2021-10-06 Abu Dhabi Polymers Co. Ltd (Borouge) L.L.C. Polyethylene composition for film applications
WO2021013552A1 (en) 2019-07-22 2021-01-28 Abu Dhabi Polymers Co. Ltd (Borouge) L.L.C. Single site catalysed multimodal polyethylene composition
EP4019583B1 (en) 2020-12-28 2024-04-10 ABU DHABI POLYMERS CO. LTD (BOROUGE) - Sole Proprietorship L.L.C. Polyethylene composition for film applications with improved toughness and stiffness

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
KR910700259A (ko) 1989-01-12 1991-03-14 리차드 이. 림바크 T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
JPH06507630A (ja) 1991-03-22 1994-09-01 ザ　トラスティーズ　オブ　ザ　ユニバーシティ　オブ　ペンシルベニア 哺乳類ｔ細胞の応答を調節する方法
WO1993010813A1 (en) 1991-11-27 1993-06-10 THE UNITED STAES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use
US5719064A (en) 1992-08-31 1998-02-17 Oklahoma Medical Research Foundation Peptide diagnostics and therapeutics for spondyloarthropathies
NZ256237A (en) 1992-09-11 1997-05-26 Univ Washington Tolerizing t-cells to an antigen with a peptide
AU1087895A (en) 1993-11-05 1995-05-23 Pathogenesis Corporation Virus associated multiple sclerosis: treatments, prevention and diagnosis thereof
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
AU767185B2 (en) * 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7084247B2 (en) * 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases

Also Published As

Publication number Publication date
EA200601671A1 (ru) 2007-02-27
US20050202034A1 (en) 2005-09-15
AU2005221712A1 (en) 2005-09-22
WO2005087261A3 (en) 2005-12-08
CN1942202A (zh) 2007-04-04
US20060159672A1 (en) 2006-07-20
JP2007528422A (ja) 2007-10-11
ZA200607552B (en) 2008-05-28
MA28525B1 (fr) 2007-04-03
KR20070026450A (ko) 2007-03-08
AP2006003735A0 (en) 2006-10-31
MXPA06010364A (es) 2007-03-07
US7084247B2 (en) 2006-08-01
WO2005087261A2 (en) 2005-09-22
IL177961A0 (en) 2006-12-31
EP1732595A2 (en) 2006-12-20
TNSN06273A1 (en) 2007-12-03
CA2559065A1 (en) 2005-09-22
NO20064610L (no) 2006-12-04

Similar Documents

Publication Publication Date Title
BRPI0508633A (pt) identificação de antìgenos próprios e não próprios envolvidos em doenças auto-imunes
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
BR112014006376A2 (pt) terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer
BR112014017525A2 (pt) composição farmacêutica que compreende um complexo de carga de carreador polimérico e pelo menos uma proteína ou antígeno de peptídeo
BR112017015906A2 (pt) complexo compreendendo um peptídeo de penetração celular, uma carga e um agonista de peptídeo tlr
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BRPI0606148A2 (pt) anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
BRPI0909123A2 (pt) anticorpos monoclonais capazes de reagir com uma pluralidade de subtipos de vírus de influenza a
CU20110009A7 (es) Anticuerpos neutralizantes de citomegalovirus humano
ECSP10010251A (es) ANTICUERPOS MONOCLONALES QUE SE UNEN AL hGM-CSF Y COMPOSICIONES MÉDICAS QUE LOS COMPRENDEN
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
BR112014003999A2 (pt) anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
CO6602134A2 (es) Proteinas de union a antigeno especificas para componente amiloide serico p
BR112021017863A2 (pt) Proteína de ligação de antígeno de membrana específico de próstata, composição, método para produzir a proteína de ligação de antígeno de membrana específico de próstata
BR112019003307A2 (pt) anticorpo ou seu fragmento de ligação a antígeno, capaz de se conectar a um receptor humano de interleucina-6
Barderas et al. Isolation of the main allergen Fra e 1 from ash (Fraxinus excelsior) pollen: comparison of the natural and recombinant forms
Sukakul et al. Chronic paronychia and onychomadesis in pemphigus vegetans: an unusual presentation in a rare autoimmune disease
WO2004018511A3 (en) Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
BR112016002001A2 (pt) Medicamento compreendendo anticorpo antifosfolipase d4

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.